On November 22, 2023, Femasys Inc. closed the transaction. The company received $1,850,000 in its second and final tranche. The company received funding pursuant to Regulation D in the transaction from 4 investors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.15 USD | +10.58% | -9.45% | +17.95% |
20/06 | Femasys Secures CE Mark Approvals for Four Women's Health Products; Shares Up Over 14% | MT |
09/05 | Femasys Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
2.08 USD | +3.48% | -0.48% | 1.7Cr | ||
1.15 USD | +10.58% | -9.45% | 2.31Cr | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.95% | 2.31Cr | |
-4.92% | 18TCr | |
-3.70% | 10TCr | |
-5.29% | 6.69TCr | |
+10.99% | 4.67TCr | |
-7.70% | 4.51TCr | |
+5.82% | 4.16TCr | |
+15.96% | 3.05TCr | |
+14.00% | 2.43TCr | |
-6.63% | 2.36TCr |
- Stock Market
- Equities
- FEMY Stock
- News Femasys Inc.
- Femasys Inc. announced that it has received $6.85 million in funding from PharmaCyte Biotech, Inc. and other investors